Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 62
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Nucleic Acids Res ; 52(8): 4702-4722, 2024 May 08.
Artículo en Inglés | MEDLINE | ID: mdl-38572746

RESUMEN

The SERF family of proteins were originally discovered for their ability to accelerate amyloid formation. Znf706 is an uncharacterized protein whose N-terminus is homologous to SERF proteins. We show here that human Znf706 can promote protein aggregation and amyloid formation. Unexpectedly, Znf706 specifically interacts with stable, non-canonical nucleic acid structures known as G-quadruplexes. G-quadruplexes can affect gene regulation and suppress protein aggregation; however, it is unknown if and how these two activities are linked. We find Znf706 binds preferentially to parallel G-quadruplexes with low micromolar affinity, primarily using its N-terminus, and upon interaction, its dynamics are constrained. G-quadruplex binding suppresses Znf706's ability to promote protein aggregation. Znf706 in conjunction with G-quadruplexes therefore may play a role in regulating protein folding. RNAseq analysis shows that Znf706 depletion specifically impacts the mRNA abundance of genes that are predicted to contain high G-quadruplex density. Our studies give insight into how proteins and G-quadruplexes interact, and how these interactions affect both partners and lead to the modulation of protein aggregation and cellular mRNA levels. These observations suggest that the SERF family of proteins, in conjunction with G-quadruplexes, may have a broader role in regulating protein folding and gene expression than previously appreciated.


Asunto(s)
Proteínas de Unión al ADN , G-Cuádruplex , Agregado de Proteínas , Humanos , Amiloide/metabolismo , Amiloide/química , Amiloide/genética , Transición de Fase , Unión Proteica , ARN Mensajero/metabolismo , ARN Mensajero/genética , ARN Mensajero/química , Proteínas de Unión al ADN/química , Proteínas de Unión al ADN/metabolismo
2.
Proc Natl Acad Sci U S A ; 120(28): e2220190120, 2023 07 11.
Artículo en Inglés | MEDLINE | ID: mdl-37399401

RESUMEN

The MYC proto-oncogene contributes to the pathogenesis of more than half of human cancers. Malignant transformation by MYC transcriptionally up-regulates the core pre-mRNA splicing machinery and causes misregulation of alternative splicing. However, our understanding of how splicing changes are directed by MYC is limited. We performed a signaling pathway-guided splicing analysis to identify MYC-dependent splicing events. These included an HRAS cassette exon repressed by MYC across multiple tumor types. To molecularly dissect the regulation of this HRAS exon, we used antisense oligonucleotide tiling to identify splicing enhancers and silencers in its flanking introns. RNA-binding motif prediction indicated multiple binding sites for hnRNP H and hnRNP F within these cis-regulatory elements. Using siRNA knockdown and cDNA expression, we found that both hnRNP H and F activate the HRAS cassette exon. Mutagenesis and targeted RNA immunoprecipitation implicate two downstream G-rich elements in this splicing activation. Analyses of ENCODE RNA-seq datasets confirmed hnRNP H regulation of HRAS splicing. Analyses of RNA-seq datasets across multiple cancers showed a negative correlation of HNRNPH gene expression with MYC hallmark enrichment, consistent with the effect of hnRNP H on HRAS splicing. Interestingly, HNRNPF expression showed a positive correlation with MYC hallmarks and thus was not consistent with the observed effects of hnRNP F. Loss of hnRNP H/F altered cell cycle progression and induced apoptosis in the PC3 prostate cancer cell line. Collectively, our results reveal mechanisms for MYC-dependent regulation of splicing and point to possible therapeutic targets in prostate cancers.


Asunto(s)
Ribonucleoproteína Heterogénea-Nuclear Grupo F-H , Neoplasias de la Próstata , Masculino , Humanos , Ribonucleoproteína Heterogénea-Nuclear Grupo F-H/genética , Ribonucleoproteína Heterogénea-Nuclear Grupo F-H/metabolismo , Precursores del ARN/genética , Precursores del ARN/metabolismo , Empalme del ARN/genética , Proteínas de Unión al ARN/metabolismo , Exones/genética , Empalme Alternativo/genética , Neoplasias de la Próstata/genética , Proteínas Proto-Oncogénicas p21(ras)/genética , Proteínas Proto-Oncogénicas p21(ras)/metabolismo
3.
Proc Natl Acad Sci U S A ; 120(21): e2221116120, 2023 05 23.
Artículo en Inglés | MEDLINE | ID: mdl-37192158

RESUMEN

Alternative splicing (AS) is prevalent in cancer, generating an extensive but largely unexplored repertoire of novel immunotherapy targets. We describe Isoform peptides from RNA splicing for Immunotherapy target Screening (IRIS), a computational platform capable of discovering AS-derived tumor antigens (TAs) for T cell receptor (TCR) and chimeric antigen receptor T cell (CAR-T) therapies. IRIS leverages large-scale tumor and normal transcriptome data and incorporates multiple screening approaches to discover AS-derived TAs with tumor-associated or tumor-specific expression. In a proof-of-concept analysis integrating transcriptomics and immunopeptidomics data, we showed that hundreds of IRIS-predicted TCR targets are presented by human leukocyte antigen (HLA) molecules. We applied IRIS to RNA-seq data of neuroendocrine prostate cancer (NEPC). From 2,939 NEPC-associated AS events, IRIS predicted 1,651 epitopes from 808 events as potential TCR targets for two common HLA types (A*02:01 and A*03:01). A more stringent screening test prioritized 48 epitopes from 20 events with "neoantigen-like" NEPC-specific expression. Predicted epitopes are often encoded by microexons of ≤30 nucleotides. To validate the immunogenicity and T cell recognition of IRIS-predicted TCR epitopes, we performed in vitro T cell priming in combination with single-cell TCR sequencing. Seven TCRs transduced into human peripheral blood mononuclear cells (PBMCs) showed high activity against individual IRIS-predicted epitopes, providing strong evidence of isolated TCRs reactive to AS-derived peptides. One selected TCR showed efficient cytotoxicity against target cells expressing the target peptide. Our study illustrates the contribution of AS to the TA repertoire of cancer cells and demonstrates the utility of IRIS for discovering AS-derived TAs and expanding cancer immunotherapies.


Asunto(s)
Neoplasias , Precursores del ARN , Masculino , Humanos , Precursores del ARN/metabolismo , Empalme Alternativo , Leucocitos Mononucleares/metabolismo , Receptores de Antígenos de Linfocitos T , Epítopos de Linfocito T , Inmunoterapia , Antígenos de Neoplasias , Péptidos/metabolismo , Neoplasias/genética , Neoplasias/terapia
4.
Am J Hum Genet ; 107(2): 196-210, 2020 08 06.
Artículo en Inglés | MEDLINE | ID: mdl-32589925

RESUMEN

A major question in human genetics is how sequence variants of broadly expressed genes produce tissue- and cell type-specific molecular phenotypes. Genetic variation of alternative splicing is a prevalent source of transcriptomic and proteomic diversity in human populations. We investigated splicing quantitative trait loci (sQTLs) in 1,209 samples from 13 human brain regions, using RNA sequencing (RNA-seq) and genotype data from the Genotype-Tissue Expression (GTEx) project. Hundreds of sQTLs were identified in each brain region. Some sQTLs were shared across brain regions, whereas others displayed regional specificity. These "regionally ubiquitous" and "regionally specific" sQTLs showed distinct positional distributions of single-nucleotide polymorphisms (SNPs) within and outside essential splice sites, respectively, suggesting their regulation by distinct molecular mechanisms. Integrating the binding motifs and expression patterns of RNA binding proteins with exon splicing profiles, we uncovered likely causal variants underlying brain region-specific sQTLs. Notably, SNP rs17651213 created a putative binding site for the splicing factor RBFOX2 and was associated with increased splicing of MAPT exon 3 in cerebellar tissues, where RBFOX2 was highly expressed. Overall, our study reveals a more comprehensive spectrum and regional variation of sQTLs in human brain and demonstrates that such regional variation can be used to fine map potential causal variants of sQTLs and their associated neurological diseases.


Asunto(s)
Encéfalo/metabolismo , Polimorfismo de Nucleótido Simple/genética , Sitios de Carácter Cuantitativo/genética , Empalme del ARN/genética , Exones/genética , Humanos , Proteómica/métodos , Proteínas de Unión al ARN/genética , Transcriptoma/genética
5.
Proc Natl Acad Sci U S A ; 117(10): 5269-5279, 2020 03 10.
Artículo en Inglés | MEDLINE | ID: mdl-32086391

RESUMEN

We sought to define the landscape of alternative pre-mRNA splicing in prostate cancers and the relationship of exon choice to known cancer driver alterations. To do so, we compiled a metadataset composed of 876 RNA-sequencing (RNA-Seq) samples from five publicly available sources representing a range of prostate phenotypes from normal tissue to drug-resistant metastases. We subjected these samples to exon-level analysis with rMATS-turbo, purpose-built software designed for large-scale analyses of splicing, and identified 13,149 high-confidence cassette exon events with variable incorporation across samples. We then developed a computational framework, pathway enrichment-guided activity study of alternative splicing (PEGASAS), to correlate transcriptional signatures of 50 different cancer driver pathways with these alternative splicing events. We discovered that Myc signaling was correlated with incorporation of a set of 1,039 cassette exons enriched in genes encoding RNA binding proteins. Using a human prostate epithelial transformation assay, we confirmed the Myc regulation of 147 of these exons, many of which introduced frameshifts or encoded premature stop codons. Our results connect changes in alternative pre-mRNA splicing to oncogenic alterations common in prostate and many other cancers. We also establish a role for Myc in regulating RNA splicing by controlling the incorporation of nonsense-mediated decay-determinant exons in genes encoding RNA binding proteins.


Asunto(s)
Neoplasias de la Próstata/metabolismo , Proteínas Proto-Oncogénicas c-myc/metabolismo , Precursores del ARN/metabolismo , Empalme del ARN/genética , Adenocarcinoma/genética , Adenocarcinoma/metabolismo , Neoplasias de la Mama/genética , Neoplasias de la Mama/metabolismo , Línea Celular Tumoral , Codón de Terminación/genética , Simulación por Computador , Conjuntos de Datos como Asunto , Resistencia a Antineoplásicos/genética , Exones , Femenino , Mutación del Sistema de Lectura , Humanos , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/metabolismo , Masculino , Neoplasias de la Próstata/genética , Proteínas Proto-Oncogénicas c-myc/genética , RNA-Seq , Transducción de Señal , Programas Informáticos
6.
Pharm Stat ; 22(6): 978-994, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37415413

RESUMEN

The response of immunogenecity anti-drug antibody (ADA) generally includes biological and analytical variability. The nature of biological and analytical variations may lead to a variety of symmetric and asymmetric ADA data. As a result, current statistical methods may yield unreliable results because these methods assume special types of symmetric or asymmetric ADA data. In this paper, we survey and compare parametric models that are useful for analyzing a variety of asymmetric data that have rarely been used to calculate assay cut points. These models include symmetric distributions as limiting case; therefore, they are useful in the analysis of a variety of symmetric data. We also investigate two nonparametric approaches that have received little attention in screening cut point calculations. A simulation study was conducted to compare the performance of the methods. We evaluate the methods using four published different types of data, and make recommendations concerning the use of the methods.


Asunto(s)
Anticuerpos , Humanos , Simulación por Computador
7.
Pharm Stat ; 19(3): 230-242, 2020 05.
Artículo en Inglés | MEDLINE | ID: mdl-31762118

RESUMEN

Potency bioassays are used to measure biological activity. Consequently, potency is considered a critical quality attribute in manufacturing. Relative potency is measured by comparing the concentration-response curves of a manufactured test batch with that of a reference standard. If the curve shapes are deemed similar, the test batch is said to exhibit constant relative potency with the reference standard, a critical requirement for calibrating the potency of the final drug product. Outliers in bioassay potency data may result in the false acceptance/rejection of a bad/good sample and, if accepted, may yield a biased relative potency estimate. To avoid these issues, the USP<1032> recommends the screening of bioassay data for outliers prior to performing a relative potency analysis. In a recently published work, the effects of one or more outliers, outlier size, and outlier type on similarity testing and estimation of relative potency were thoroughly examined, confirming the USP<1032> outlier guidance. As a follow-up, several outlier detection methods, including those proposed by the USP<1010>, are evaluated and compared in this work through computer simulation. Two novel outlier detection methods are also proposed. The effects of outlier removal on similarity testing and estimation of relative potency were evaluated, resulting in recommendations for best practice.


Asunto(s)
Bioensayo/estadística & datos numéricos , Modelos Estadísticos , Proyectos de Investigación/estadística & datos numéricos , Bioensayo/normas , Interpretación Estadística de Datos , Relación Dosis-Respuesta a Droga , Estándares de Referencia
8.
J Biopharm Stat ; 29(6): 1011-1023, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30712462

RESUMEN

Parallelism in bioassay is a synonym of similarity between two concentration-response curves. Before the determination of relative potency in bioassays, it is necessary to test for and claim parallelism between the pair of concentration-response curves of reference standard and test sample. Methods for parallelism testing include p-value-based significance tests and interval-based equivalence tests. Most of the latter approaches make statistical inference about the equivalence of parameters of the concentration-response curve models. An apparent drawback of such methods is that equivalence in model parameters does not guarantee similarity between the reference and test sample. In contrast, a Bayesian method was recently proposed that directly tests the parallelism hypothesis that the concentration-response curve of the test sample is a horizontal shift of that of the reference. In other words, the testing sample is a dilution or concentration of the reference standard. The Bayesian approach is shown to protect against type I error and provides sufficient statistical power for parallelism testing. In practice, however, it is challenging to implement the method as it requires both specialized Bayesian software and a relatively long run time. In this paper, we propose a frequentist version of the test with split-second run time. The empirical properties of the frequentist parallelism test method are evaluated and compared with the original Bayesian method. It is demonstrated that the frequentist method is both fast and reliable for parallelism testing for a variety of concentration-response models.


Asunto(s)
Bioensayo , Biofarmacia , Modelos Estadísticos , Teorema de Bayes , Bioensayo/métodos , Bioensayo/estadística & datos numéricos , Biofarmacia/métodos , Biofarmacia/estadística & datos numéricos , Simulación por Computador , Relación Dosis-Respuesta a Droga , Método de Montecarlo , Dinámicas no Lineales
9.
Pharm Stat ; 18(6): 688-699, 2019 11.
Artículo en Inglés | MEDLINE | ID: mdl-31140720

RESUMEN

Linear models are generally reliable methods for analyzing tumor growth in vivo, with drug effectiveness being represented by the steepness of the regression slope. With immunotherapy, however, not all tumor growth follows a linear pattern, even after log transformation. Tumor kinetics models are mechanistic models that describe tumor proliferation and tumor killing macroscopically, through a set of differential equations. In drug combination studies, although an additional drug-drug interaction term can be added to such models, however, the drug interactions suggested by tumor kinetics models cannot be translated directly into synergistic effects. We have developed a novel statistical approach that simultaneously models tumor growth in control, monotherapy, and combination therapy groups. This approach makes it possible to test for synergistic effects directly and to compare such effects among different studies.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Inmunoterapia/métodos , Modelos Teóricos , Neoplasias/tratamiento farmacológico , Interacciones Farmacológicas , Sinergismo Farmacológico , Humanos , Cinética , Modelos Lineales , Neoplasias/patología , Resultado del Tratamiento
10.
Pharm Stat ; 17(6): 701-709, 2018 11.
Artículo en Inglés | MEDLINE | ID: mdl-30112804

RESUMEN

The USP<1032> guidelines recommend the screening of bioassay data for outliers prior to performing a relative potency (RP) analysis. The guidelines, however, do not offer advice on the size or type of outlier that should be removed prior to model fitting and calculation of RP. Computer simulation was used to investigate the consequences of ignoring the USP<1032> guidance to remove outliers. For biotherapeutics and vaccines, outliers in potency data may result in the false acceptance/rejection of a bad/good lot of drug product. Biological activity, measured through a potency bioassay, is considered a critical quality attribute in manufacturing. If the concentration-response potency curve of a test sample is deemed to be similar in shape to that of the reference standard, the curves are said to exhibit constant RP, an essential criterion for the interpretation of a RP. One or more outliers in the concentration-response data, however, may result in a failure to declare similarity or may yield a biased RP estimate. Concentration-response curves for test and reference were computer generated with constant RP from four-parameter logistic curves. Single outlier, multiple outlier, and whole-curve outlier scenarios were explored for their effects on the similarity testing and on the RP estimation. Though the simulations point to situations for which outlier removal is unnecessary, the results generally support the USP<1032> recommendation and illustrate the impact on the RP calculation when application of outlier removal procedures are discounted.


Asunto(s)
Bioensayo , Interpretación Estadística de Datos , Simulación por Computador , Relación Dosis-Respuesta a Droga , Guías como Asunto , Humanos
11.
J Proteome Res ; 16(9): 3124-3136, 2017 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-28745510

RESUMEN

Mass spectrometry is being used to identify protein biomarkers that can facilitate development of drug treatment. Mass spectrometry-based labeling proteomic experiments result in complex proteomic data that is hierarchical in nature often with small sample size studies. The generalized linear model (GLM) is the most popular approach in proteomics to compare protein abundances between groups. However, GLM does not address all the complexities of proteomics data such as repeated measures and variance heterogeneity. Linear models for microarray data (LIMMA) and mixed models are two approaches that can address some of these data complexities to provide better statistical estimates. We compared these three statistical models (GLM, LIMMA, and mixed models) under two different normalization approaches (quantile normalization and median sweeping) to demonstrate when each approach is the best for tagged proteins. We evaluated these methods using a spiked-in data set of known protein abundances, a systemic lupus erythematosus (SLE) data set, and simulated data from multiplexed labeling experiments that use tandem mass tags (TMT). Data are available via ProteomeXchange with identifier PXD005486. We found median sweeping to be a preferred approach of data normalization, and with this normalization approach there was overlap with findings across all methods with GLM being a subset of mixed models. The conclusion is that the mixed model had the best type I error with median sweeping, whereas LIMMA had the better overall statistical properties regardless of normalization approaches.


Asunto(s)
Proteínas Sanguíneas/aislamiento & purificación , Proteínas de Escherichia coli/aislamiento & purificación , Lupus Eritematoso Sistémico/genética , Modelos Estadísticos , Análisis por Matrices de Proteínas/estadística & datos numéricos , Proteínas Sanguíneas/química , Escherichia coli/genética , Escherichia coli/metabolismo , Proteínas de Escherichia coli/química , Humanos , Lupus Eritematoso Sistémico/sangre , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/patología , Proteómica/métodos , Proteómica/estadística & datos numéricos , Coloración y Etiquetado/métodos
12.
Biologicals ; 49: 46-50, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28743417

RESUMEN

Changes of manufacturing processes are common. It is required by the regulatory agencies that manufacturers establish adequate and appropriate comparability between pre-change and post-change products. The goals of comparability assessments are to demonstrate the comparability and consistency of product quality before and after change and to demonstrate that the changes do not have an adverse effect on safety and efficacy of the drug products. Accelerated or stressed stability studies may shed light on drug quality under stressed environmental conditions and on product differences in the degradation pathways. Comparability of accelerated stability data may provide further evidence on the impact of process change. Equivalence test has been recommended to demonstrate the comparability of stability profiles for accelerated stability studies. Selection of appropriate acceptance criteria for determining comparability is one of the most challenging steps in the comparability studies. Because of the inherent heterogeneity of biologics, the stability profiles may vary considerably from batch to batch. It is more challenging to set the acceptance criteria for comparing the accelerated stability data for biologics. In this article, we present an approach for determining the acceptance criteria and necessary sample sizes for accelerated comparability studies for biologics.


Asunto(s)
Productos Biológicos/química , Modelos Químicos , Estabilidad de Medicamentos
13.
J Biopharm Stat ; 26(5): 992-1002, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26882145

RESUMEN

In a bridging study, the plasma drug concentration-time curve is generally used to assess bioequivalence between the two formulations. Selected pharmacokinetic (PK) parameters including the area under the concentration-time curve, the maximum plasma concentration or peak exposure (Cmax), and drug half-life (T1/2) are compared to ensure comparable bioavailability of the two formulations. Comparability in these PK parameters, however, does not necessarily imply equivalence of the entire concentration-time profile. In this article, we propose an alternative metric of equivalence based on the maximum difference between PK profiles of the two formulations. A test procedure based on Bayesian analysis and accounting for uncertainties in model parameters is developed. Through both theoretical derivation and empirical simulation, it is shown that the new method provides better control over consumer's risk.


Asunto(s)
Disponibilidad Biológica , Preparaciones Farmacéuticas/análisis , Farmacocinética , Equivalencia Terapéutica , Teorema de Bayes , Semivida , Humanos
14.
J Biopharm Stat ; 25(2): 234-46, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25358029

RESUMEN

We propose a method for determining the criticality of residual host cell DNA, which is characterized through two attributes, namely the size and amount of residual DNA in biopharmaceutical product. By applying a mechanistic modeling approach to the problem, we establish the linkage between residual DNA and product safety measured in terms of immunogenicity, oncogenicity, and infectivity. Such a link makes it possible to establish acceptable ranges of residual DNA size and amount. Application of the method is illustrated through two real-life examples related to a vaccine manufactured in Madin Darby Canine Kidney cell line and a monoclonal antibody using Chinese hamster ovary (CHO) cell line as host cells.


Asunto(s)
Biofarmacia/estadística & datos numéricos , ADN/análisis , Contaminación de Medicamentos/estadística & datos numéricos , Modelos Estadísticos , Tecnología Farmacéutica/estadística & datos numéricos , Animales , Anticuerpos Monoclonales/biosíntesis , Anticuerpos Monoclonales/genética , Biofarmacia/normas , Células CHO , Química Farmacéutica , Seguridad de Productos para el Consumidor , Cricetulus , Interpretación Estadística de Datos , Perros , Guías como Asunto , Humanos , Vacunas contra la Influenza/biosíntesis , Vacunas contra la Influenza/genética , Vacunas contra la Influenza/normas , Células de Riñón Canino Madin Darby , Control de Calidad , Medición de Riesgo , Tecnología Farmacéutica/métodos , Tecnología Farmacéutica/normas
15.
J Biopharm Stat ; 25(2): 339-50, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25356663

RESUMEN

Validation of linearity is a regulatory requirement. Although many methods are proposed, they suffer from several deficiencies including difficulties of setting fit-for-purpose acceptable limits, dependency on concentration levels used in linearity experiment, and challenges in implementation for statistically lay users. In this article, a statistical procedure for testing linearity is proposed. The method uses a two one-sided test (TOST) of equivalence to evaluate the bias that can result from approximating a higher-order polynomial response with a linear function. By using orthogonal polynomials and generalized pivotal quantity analysis, the method provides a closed-form solution, thus making linearity testing easy to implement.


Asunto(s)
Biofarmacia/estadística & datos numéricos , Modelos Estadísticos , Tecnología Farmacéutica/estadística & datos numéricos , Sesgo , Biofarmacia/normas , Química Farmacéutica , Intervalos de Confianza , Interpretación Estadística de Datos , Guías como Asunto , Modelos Lineales , Control de Calidad , Valores de Referencia , Reproducibilidad de los Resultados , Tecnología Farmacéutica/métodos , Tecnología Farmacéutica/normas
16.
J Biopharm Stat ; 25(2): 295-306, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25356500

RESUMEN

Administration of biological therapeutics can generate undesirable immune responses that may induce anti-drug antibodies (ADAs). Immunogenicity can negatively affect patients, ranging from mild reactive effect to hypersensitivity reactions or even serious autoimmune diseases. Assessment of immunogenicity is critical as the ADAs can adversely impact the efficacy and safety of the drug products. Well-developed and validated immunogenicity assays are required by the regulatory agencies as tools for immunogenicity assessment. Key to the development and validation of an immunogenicity assay is the determination of a cut point, which serves as the threshold for classifying patients as ADA positive(reactive) or negative. In practice, the cut point is determined as either the quantile of a parametric or nonparametric empirical distribution. The parametric method, which is often based on a normality assumption, may lead to biased cut point estimates when the normality assumption is violated. The non-parametric method, which yields unbiased estimates of the cut point, may have low efficiency when the sample size is small. As the distribution of immune responses are often skewed and sometimes heavy-tailed, we propose two non-normal random effects models for cut point determination. The random effects, following a skew-t or log-gamma distribution, can incorporate the skewed and heavy-tailed responses and the correlation among repeated measurements. Simulation study is conducted to compare the proposed method with the current normal and nonparametric alternatives. The proposed models are also applied to a real dataset generated from assay validation studies.


Asunto(s)
Productos Biológicos/inmunología , Biofarmacia/estadística & datos numéricos , Modelos Estadísticos , Tecnología Farmacéutica/estadística & datos numéricos , Animales , Teorema de Bayes , Productos Biológicos/efectos adversos , Biofarmacia/normas , Química Farmacéutica , Simulación por Computador , Interpretación Estadística de Datos , Guías como Asunto , Humanos , Análisis Numérico Asistido por Computador , Control de Calidad , Reproducibilidad de los Resultados , Medición de Riesgo , Tamaño de la Muestra , Estadísticas no Paramétricas , Tecnología Farmacéutica/métodos , Tecnología Farmacéutica/normas
17.
J Biopharm Stat ; 25(2): 351-71, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25357203

RESUMEN

Dissolution (or in vitro release) studies constitute an important aspect of pharmaceutical drug development. One important use of such studies is for justifying a biowaiver for post-approval changes which requires establishing equivalence between the new and old product. We propose a statistically rigorous modeling approach for this purpose based on the estimation of what we refer to as the F2 parameter, an extension of the commonly used f2 statistic. A Bayesian test procedure is proposed in relation to a set of composite hypotheses that capture the similarity requirement on the absolute mean differences between test and reference dissolution profiles. Several examples are provided to illustrate the application. Results of our simulation study comparing the performance of f2 and the proposed method show that our Bayesian approach is comparable to or in many cases superior to the f2 statistic as a decision rule. Further useful extensions of the method, such as the use of continuous-time dissolution modeling, are considered.


Asunto(s)
Biofarmacia/estadística & datos numéricos , Modelos Estadísticos , Preparaciones Farmacéuticas/química , Tecnología Farmacéutica/estadística & datos numéricos , Teorema de Bayes , Biofarmacia/normas , Química Farmacéutica , Simulación por Computador , Interpretación Estadística de Datos , Guías como Asunto , Cinética , Método de Montecarlo , Análisis Multivariante , Preparaciones Farmacéuticas/normas , Control de Calidad , Solubilidad , Tecnología Farmacéutica/métodos , Tecnología Farmacéutica/normas
18.
Pharm Stat ; 14(4): 332-40, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25962689

RESUMEN

Under the Loewe additivity, constant relative potency between two drugs is a sufficient condition for the two drugs to be additive. Implicit in this condition is that one drug acts like a dilution of the other. Geometrically, it means that the dose-response curve of one drug is a copy of another that is shifted horizontally by a constant over the log-dose axis. Such phenomenon is often referred to as parallelism. Thus, testing drug additivity is equivalent to the demonstration of parallelism between two dose-response curves. Current methods used for testing parallelism are usually based on significance tests for differences between parameters in the dose-response curves of the monotherapies. A p-value of less than 0.05 is indicative of non-parallelism. The p-value-based methods, however, may be fundamentally flawed because an increase in either sample size or precision of the assay used to measure drug effect may result in more frequent rejection of parallel lines for a trivial difference. Moreover, similarity (difference) between model parameters does not necessarily translate into the similarity (difference) between the two response curves. As a result, a test may conclude that the model parameters are similar (different), yet there is little assurance on the similarity between the two dose-response curves. In this paper, we introduce a Bayesian approach to directly test the hypothesis that the two drugs have a constant relative potency. An important utility of our proposed method is in aiding go/no-go decisions concerning two drug combination studies. It is illustrated with both a simulated example and a real-life example.


Asunto(s)
Ensayos Clínicos como Asunto/estadística & datos numéricos , Relación Dosis-Respuesta a Droga , Proyectos de Investigación/estadística & datos numéricos , Teorema de Bayes , Ensayos Clínicos como Asunto/métodos , Simulación por Computador , Interpretación Estadística de Datos , Sinergismo Farmacológico , Quimioterapia Combinada , Humanos , Análisis de los Mínimos Cuadrados , Modelos Lineales , Modelos Logísticos
19.
J Biopharm Stat ; 24(3): 535-45, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24697778

RESUMEN

Past decades have seen a rapid growth of biopharmaceutical products on the market. The administration of such large molecules can generate antidrug antibodies that can induce unwanted immune reactions in the recipients. Assessment of immunogenicity is required by regulatory agencies in clinical and nonclinical development, and this demands a well-validated assay. One of the important performance characteristics during assay validation is the cut point, which serves as a threshold between positive and negative samples. To precisely determine the cut point, a sufficiently large data set is often needed. However, there is no guideline other than some rule-of-thumb recommendations for sample size requirement in immunoassays. In this article, we propose a systematic approach to sample size determination for immunoassays and provide tables that facilitate its applications by scientists.


Asunto(s)
Anticuerpos/análisis , Productos Biológicos/inmunología , Inmunoensayo/estadística & datos numéricos , Modelos Estadísticos , Tamaño de la Muestra , Análisis de Varianza , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/inmunología , Humanos , Distribuciones Estadísticas
20.
COPD ; 11(2): 226-35, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24111823

RESUMEN

Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous disease with a wide range of clinical phenotypes that vary from predominantly airway disease (chronic bronchitis) to predominantly parenchymal disease (emphysema). Current advances for the treatment of COPD are increasingly focused on targeted treatments and development of novel biomarker-based diagnostics (Dx)'s to select the patients most likely to benefit. Clinical trial planning and design with biomarkers includes additional considerations beyond those for conventional trials in un-selected populations, e.g., the heterogeneity of COPD phenotypes in the population, the ability of a biomarker to predict clinically meaningful phenotypes that are differentially associated with the response to a targeted treatment, and the data needed to make Go/No Go decisions during clinical development. We developed the Clinical Trial Object Oriented Research Application (CTOORA), a computer-aided clinical trial simulator of COPD patient outcomes, to inform COPD trial planning with biomarkers. CTOORA provides serial projections of trial success for a range of hypothetical and plausible scenarios of interest. In the absence of data, CTOORA can identify characteristics of a biomarker-based Dx needed to provide a meaningful advantage when used in a clinical trial. We present a case study in which CTOORA is used to identify the scenarios for which a biomarker may be used successfully in clinical development. CTOORA is a tool for robust clinical trial planning with biomarkers, to guide early-to-late stage development that is positioned for success.


Asunto(s)
Biomarcadores/metabolismo , Ensayos Clínicos como Asunto , Simulación por Computador , Toma de Decisiones Asistida por Computador , Enfermedad Pulmonar Obstructiva Crónica/diagnóstico , Enfermedad Pulmonar Obstructiva Crónica/metabolismo , Humanos , Enfermedad Pulmonar Obstructiva Crónica/terapia , Proyectos de Investigación , Sensibilidad y Especificidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA